{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T03:24:14Z","timestamp":1791775454532,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1111\/jth.15700","type":"journal-article","created":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T04:39:22Z","timestamp":1647319162000},"page":"1400-1411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":104,"title":["Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2108-8286","authenticated-orcid":false,"given":"Stefan","family":"Heitmeier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayken","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Tersteegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Dietze\u2010Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Glunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Gerdes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Laux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Stampfuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Roehrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1111\/jth.15700_bb0010","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/ATVBAHA.117.309664","article-title":"2017 scientific sessions sol sherry distinguished lecture in thrombosis","volume":"38","author":"Weitz","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1111\/jth.15700_bb0015","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.amjcard.2017.10.035","article-title":"Meta\u2010analysis of the safety and efficacy of the oral anticoagulant agents (apixaban, rivaroxaban, dabigatran) in patients with acute coronary syndrome","volume":"121","author":"Khan","year":"2018","journal-title":"Am J Cardiol"},{"issue":"14","key":"10.1111\/jth.15700_bb0020","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1111\/jth.15700_bb0025","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1111\/jth.15700_bb0030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1111\/jth.15700_bb0035","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2009-09-199182","article-title":"Structure and function of factor XI","volume":"115","author":"Emsley","year":"2010","journal-title":"Blood"},{"issue":"24","key":"10.1111\/jth.15700_bb0040","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1016\/j.jmb.2019.09.008","article-title":"Allosteric inhibition as a new mode of action for BAY 1213790, a neutralizing antibody targeting the activated form of coagulation factor XI","volume":"431","author":"Schaefer","year":"2019","journal-title":"J Mol Biol"},{"issue":"4","key":"10.1111\/jth.15700_bb0045","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1538-7836.2005.01236.x","article-title":"Effects of factor IX or factor XI deficiency on ferric chloride\u2010induced carotid artery occlusion in mice","volume":"3","author":"Wang","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"9","key":"10.1111\/jth.15700_bb0050","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1111\/j.1538-7836.2006.02093.x","article-title":"Effects of factor XI deficiency on ferric chloride\u2010induced vena cava thrombosis in mice","volume":"4","author":"Wang","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"19","key":"10.1111\/jth.15700_bb0055","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1182\/blood-2010-02-270918","article-title":"A role for factor XIIa\u2013mediated factor XI activation in thrombus formation in vivo","volume":"116","author":"Cheng","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1111\/jth.15700_bb0060","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2011-10-387134","article-title":"Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys","volume":"119","author":"Younis","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1111\/jth.15700_bb0065","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood-2008-06-163675","article-title":"Prevention of vascular graft occlusion and thrombus\u2010associated thrombin generation by inhibition of factor XI","volume":"113","author":"Tucker","year":"2009","journal-title":"Blood"},{"issue":"7","key":"10.1111\/jth.15700_bb0070","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1111\/j.1538-7836.2006.01973.x","article-title":"Factor XI contributes to thrombus propagation on injured neointima of the rabbit iliac artery","volume":"4","author":"Yamashita","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"13","key":"10.1111\/jth.15700_bb0075","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1182\/blood-2013-12-540872","article-title":"Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits","volume":"123","author":"Yau","year":"2014","journal-title":"Blood"},{"issue":"22","key":"10.1111\/jth.15700_bb0080","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood-2010-04-277798","article-title":"Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk","volume":"116","author":"Zhang","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1111\/jth.15700_bb0085","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","article-title":"Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events","volume":"129","author":"Preis","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1111\/jth.15700_bb0090","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1182\/blood-2007-10-120139","article-title":"Reduced incidence of ischemic stroke in patients with severe factor XI deficiency","volume":"111","author":"Salomon","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1111\/jth.15700_bb0095","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial","volume":"323","author":"Weitz","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"10.1111\/jth.15700_bb0100","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"B\u00fcller","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1111\/jth.15700_bb0105","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1111\/jth.15700_bb0110","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N Engl J Med"},{"issue":"S1","key":"10.1111\/jth.15700_bb0115","first-page":"40","article-title":"A way to make rodent FXIa accessible to human FXIa small molecule inhibitors","volume":"3","author":"Visser","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"10.1111\/jth.15700_bb0120","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/jth.15588","article-title":"Milvexian, an orally bioavailable, small\u2010molecule, reversible, direct inhibitor of factor XIa: in vitro studies and in vivo evaluation in experimental thrombosis in rabbits","volume":"20","author":"Wong","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1111\/jth.15700_bb0125","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/rth2.12186","article-title":"BAY\u00a01213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokinetics","volume":"3","author":"Thomas","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"13","key":"10.1111\/jth.15700_bb0130","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2018-10-880849","article-title":"MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans","volume":"133","author":"Koch","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1111\/jth.15700_bb0135","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/cts.13148","article-title":"First\u2010in\u2010human study of milvexian, an oral, direct, small molecule factor XIa inhibitor","volume":"15","author":"Perera","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"2","key":"10.1111\/jth.15700_bb0140","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/jth.15577","article-title":"Pharmacokinetics and pharmacodynamics of abelacimab (MAA868), a novel dual inhibitor of factor XI and factor XIa","volume":"20","author":"Yi","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"10","key":"10.1111\/jth.15700_bb0145","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1111\/jth.15439","article-title":"First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa","volume":"19","author":"Thomas","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15700_bb0150","doi-asserted-by":"crossref","DOI":"10.1111\/bcp.15230","article-title":"Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: a randomized phase 1 multiple\u2010dose study","author":"Kubitza","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"10.1111\/jth.15700_bb0155","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1161\/CIRCRESAHA.115.306823","article-title":"Animal models of thrombosis from Zebrafish to nonhuman primates: use in the elucidation of new pathologic pathways and the development of antithrombotic drugs","volume":"118","author":"Jagadeeswaran","year":"2016","journal-title":"Circ Res"},{"issue":"10","key":"10.1111\/jth.15700_bb0160","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1111\/j.1538-7836.2008.03092.x","article-title":"Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits","volume":"6","author":"Wong","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1111\/jth.15700_bb0165","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/j.1538-7836.2007.02526.x","article-title":"Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis","volume":"5","author":"Wienen","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1111\/jth.15700_bb0170","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1538-7836.2005.01166.x","article-title":"In vitro and in vivo studies of the novel antithrombotic agent BAY 59\u20107939\u2010\u2010an oral, direct factor Xa inhibitor","volume":"3","author":"Perzborn","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"22","key":"10.1111\/jth.15700_bb0175","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1021\/jm070245n","volume":"50","author":"Pinto","year":"2007","journal-title":"J Med Chem"},{"issue":"03","key":"10.1111\/jth.15700_bb0180","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1160\/TH06-11-0620","article-title":"Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)\u2010\u2010an oral, direct factor Xa inhibitor","volume":"97","author":"Biemond","year":"2007","journal-title":"Thromb Haemost"}],"updated-by":[{"DOI":"10.1111\/jth.15845","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000}}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15700","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.15700","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622001957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622001957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15700","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,15]],"date-time":"2023-01-15T19:52:28Z","timestamp":1673812348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622001957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1538783622001957"],"URL":"https:\/\/doi.org\/10.1111\/jth.15700","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.15700","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 Bayer AG. Journal of Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}]}}